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Abstract
Background: The hypoglycemic effect of bezafibrate is well established, but administration to a large population
of patients with diabetes has not been reported. We investigated glycemic control, relationship between lipid
metabolism and HbA1c, and safety in diabetic patients treated with bezafibrate.
Methods: A prospective, observational analysis was conducted on 6,407 dyslipidemic patients suffering from
diabetes or hyperglycemia who had not received bezafibrate previously. Subanalyses were performed on the
concomitant use of diabetes drugs, diabetes duration, and baseline HbA1c levels.
Results: Bezafibrate significantly decreased HbA1c irrespective of concomitant use of other diabetes drugs in a
baseline-HbA1c-dependent manner, with patients with a shorter diabetes duration showing a greater decrease in
HbA1c than those with longer-term disease. The rate of change in triglyceride levels was significantly associated
with that in HbA1c. Adverse drug reactions occurred in 306 patients (5.1%), of which reactions in 289 were not
severe (94.4%).
Conclusions: Bezafibrate significantly improved HbA1c in patients with diabetes given individualized treatment.
Bezafibrate may offer clinicians an improved modality for the amelioration of disease course and improvement of
outcome in these patients.
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Background
The prevalence of patients with or at risk of type 2 dia-
betes is increasing rapidly in Japan, which is in the top
10 of Asian countries with respect to population diag-
nosed with diabetes and impaired glucose tolerance [1].
Hyperglycemia in patients with type 2 diabetes places
them at significant risk for cardiovascular events and
other diabetic complications [2], as shown for example
by the United Kingdom Prospective Diabetes Study
(UKPDS 35), which demonstrated a strong association
between the risk of diabetic complications and hypergly-
cemia [3]. Patients with type 2 diabetes also tend to
have higher triglyceride (TG) and lower high-density
lipoprotein cholesterol (HDL-C) levels than non-
diabetics [4]; for example, Lehto et al. reported that the
simultaneous presence of hyperglycemia with either low
HDL-C or high TG levels increased the risk of cardio-
vascular events up to three-fold in patients with type 2
diabetes [5]. Effective treatment of type 2 diabetes must
therefore involve the management of blood glucose and
lipids, including TG and HDL-C levels.
The ability of bezafibrate to reduce TG, cholesterol,
and blood glucose levels in patients with diabetes was
first reported over 30 years ago [6,7], and the drug has
become widely used for treating dyslipidemia, particu-
larly to improve TG and HDL-C levels [reviewed in [8]].
Moreover, previous research has shown that bezafibrate
functions as an agonist of PPAR nuclear transcription
factors, which play an important role in glucose and
lipid metabolism [9-13]. Although as indicated above,
bezafibrate improves lipid and glucose metabolism
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its effects in a large cohort of patients with diabetes.
Here, we conducted a 24-week prospective observa-
tional study of bezafibrate in the treatment of dyslipi-
demic patients with diabetes, designated the “Japan
BEzafibrate cliNical EFfectIveness and Tolerability (J-
BENEFIT)” study.
Methods
Subjects
This prospective observational study of dyslipidemic
patients with diabetes was conducted as post-marketing
surveillance to evaluate the efficacy and safety of bezafi-
brate therapy. We included only those patients who met
all inclusion criteria and did not have any conditions
listed in the exclusion criteria. The inclusion criteria
were as follows:
1. No prior administration of bezafibrate
2. Serum TG ≥ 1.7 mmol/l (≥ 150 mg/dl) and/or
serum total cholesterol (TC) ≥ 5.7 mmol/l (≥ 220 mg/dl)
3. Diagnosis of diabetes or most recent fasting blood
glucose (FBG) ≥ 6.1 mmol/l (≥ 110 mg/dl)
The exclusion criteria were as follows:
1. Undergoing dialysis treatment
2. Severe renal disease (on dialysis or in renal failure)
3. Blood creatinine ≥ 152.5 μmol/l (≥ 2.0 mg/dl)
4. History of bezafibrate hypersensitivity
5. Pregnant or possibly pregnant
Subjects were enrolled by centralized registration from
June 2003 to March 2005, and the study was conducted
from June 2003 to September 2005. Patients were admi-
nistered 400 mg/day bezafibrate for 24 weeks. We evalu-
ated the efficacy and safety of bezafibrate in each
analysis group. Safety was evaluated in all patients
whose case report forms were collected, except those
with protocol violations or insufficient data for safety
analysis. Efficacy was evaluated in all patients except
those with protocol noncompliance or insufficient data
for efficacy analysis from safety analysis group. Efficacy
endpoints included lipid metabolism parameters such as
TG, TC, low-density cholesterol (LDL-C), HDL-C, non-
HDL-C, and TG/HDL ratio and glucose metabolism
parameters such as FBG, HbA1c, and homeostasis
model assessment insulin resistance (HOMA-R).
Laboratory tests were performed at each of the 1,066
institutions. Efficacy endpoints were assessed at baseline
and after 24 weeks of treatment. For observations < 24
weeks, efficacy endpoints were assessed at the last mea-
surement (12 weeks treatment onward). LDL-C was cal-
culated by the Friedwald formula [18] in patients with
TG < 4.4 mmol/l. The TG/HDL-C ratio and non-HDL-
C were calculated using TC, TG, and HDL-C values.
HbA1c was measured according to the Japan Diabetes
Society’s (JDS) method [19] and then converted to the
corresponding National Glycohemoglobin Standardiza-
tion Program (NGSP) value. HbA1c value was estimated
as an NGSP-equivalent value calculated with the follow-
ing formula:
HbA1c (NGSP) =H b A 1 c(JDS) +0 . 4
considering the relational expression of HbA1c (JDS)
measured with the previous Japanese standard substance
and methods and HbA1c (NGSP) [19]. Safety endpoints
were evaluated as the incidence of adverse drug reaction
(ADR), and included laboratory value abnormalities for
which an association with bezafibrate could not be ruled
out.
Statistical analysis
All statistical analyses were performed using SAS ver-
sion 8.12 (SAS Institute). A paired t-test was used to
compare endpoints after treatment versus baseline with
two-tailed significance set at 5%. ANOVA was per-
formed to evaluate linear trends among subgroups clas-
sified by baseline HbA1c levels and duration of diabetes.
Univariate and stepwise multivariate regression analyses
were performed to evaluate independent predictors of
the change in HbA1c. The explanatory variables exam-
ined were patient age, sex, baseline BMI, baseline
HbA1c, administration of diabetes drugs during the
study, duration of diabetes, and rate of change of each
lipid including TC, LDL-C, TG, and HDL-C. This study
was conducted in compliance with good post-marketing
surveillance practice and the guidelines on the methods
for surveillance of the results of prescription drug use
issued by the Ministry of Health, Labour, and Welfare,
Japan.
Results
Patients
We enrolled 6,449 patients and collected 6,407 case
report forms. Safety was evaluated in 5,978 patients.
Patients were excluded from safety analysis for the fol-
lowing reasons, namely 1) protocol violation: some
patients did not receive bezafibrate (n = 13), had a delay
in enrollment (n = 292), and had a history of bezafibrate
treatment (n = 20); and 2) insufficient data for safety
analysis (n = 104). A total of 429 of 6407 patients were
excluded. Patients were excluded from efficacy analysis
for the following reasons: 1) protocol violation: patients
had neither TG ≥ 1.7 mmol/l nor TC ≥ 5.7 mmol/l (n =
920), or patients had neither diabetes nor FBG ≥ 6.1
mmol/l (n = 653, overlapping); 2) insufficient data for
efficacy analysis: dose or duration of bezafibrate
unknown (n = 86); data incomplete for baseline or after
administration for any one of TC, TG, and HbA1c (n =
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pretreatment with diabetes drugs, or both (n = 783);
unknown concomitant drug for treating hyperlipidemia
or unknown diabetes drug (n = 6); or both (these cases
overlapped, resulting in 2,662 cases being excluded from
safety analyses).
Patients’ backgrounds in the efficacy analysis group
are shown in Table 1. The number of patients with dia-
betes was 3,312 (99.9%), of whom 3,235 (97.6%) were
diagnosed with type 2 diabetes. Mean duration of dia-
betes was 6.6 ± 5.9 years. A total of 602 (18.2%) and
1,977 (59.6%) patients had been previously treated for
dyslipidemia and diabetes, respectively. Medication char-
acteristics of the efficacy analysis group showed that
while most patients (3,149; 95.0%) were treated for dysli-
pidemia with bezafibrate alone, 167 patients (5.0%) took
other lipid-lowering drugs concurrently (Table 2).
All patients were classified into four subgroups
according to diabetes drug administration before and
during the study as follows: diabetes drug not taken
before or during the study (n = 818, 24.7%), taken only
during the study (n = 521, 15.7%), taken only before the
study (n = 106, 3.2%) and taken before and during the
study (n = 1,871, 56.4%). Thus, a diabetes drug was
taken by 2,392 patients (72.1%) during the study. The
most frequently used diabetes drug regimen was single
administration of sulfonylureas (22.1%) followed by
combined use of sulfonylureas and an a-glucosidase
inhibitor (6.9%) (Table 2). The number of patients
receiving both monotherapy and combination use of
diabetes drugs was as follows: sulfonylureas (n = 1,505,
45.4%), glinides (n = 341, 10.3%), a-glucosidase inhibitor
(n = 685, 20.7%), biguanide (n = 550, 16.6%), thiazoli-
dine (n = 287, 8.7%), and insulin (n = 284, 8.6%) (data
not shown). All of 3,316 patients took bezafibrate at
Table 1 Characteristics of patients in the efficacy analysis
group
Characteristics of Patients n (%) or mean ± SD
Number 3316
Entry category
Type 1 diabetes, n/% 40 (1.2%)
Type 2 diabetes, n/% 3235 (97.6%)
Diabetes (diagnosis unknown), n/% 37 (1.1%)
FBG ≥ 6.1 [mmol/l], n/% 4 (0.1%)
Outpatients, n/% 3212 (96.9%)
Men, n/% 2074 (62.5%)
Age, mean/SD 61.0 ± 12.0
≥65 yeas, n/% 1400 (42.2%)
BMI (kg/m
2), mean/SD 25.7 ± 3.7
Smoking, n/% 825 (24.9%)
Alcohol consumption, n/% 1129 (34.0%)
Complication, n/% 2397 (72.3%)
Hepatic disease, n/% 339 (10.2%)
Kidney disease, n/% 51 (1.5%)
Hypertension, n/% 1614 (48.7%)
Heart disease, n/% 325 (9.8%)
Duration of hyperlipidemia (years), mean/SD 4.7 ± 4.3
Duration of diabetes (years), mean/SD 6.6 ± 5.9
Previous treatment of hyperlipidemia, n/% 602 (18.2%)
Previous treatment of diabetes, n/% 1977 (59.6%)
Total cholesterol (mmol/l), mean/SD 5.76 ± 1.03
LDL cholesterol (mmol/l), mean/SD 3.19 ± 0.95
HDL cholesterol (mmol/l), mean/SD 1.18 ± 0.33
TG (mmol/l), mean/SD 3.72 ± 2.45
HbA1c (%), mean/SD 7.69 ± 1.52
FBG (mmol/l), mean/SD 9.01 ± 3.49
aStandard Deviation
Table 2 Drug treatment
Medication n (%)
Total number of patients 3316
Concomitant administration of lipid-lowering drug during
the study
No concomitant drug 3149
(95.0%)
Concomitant administration 167 (5.0%)
statin 119 (3.6%)
others 48 (1.4%)
diabetes drug administration before and during the study
-Before- -During-
Not taken Not taken 818 (24.7%)
Not taken Taken 521 (15.7%)
Taken Not taken 106 (3.2%)
Taken Taken 1871
(56.4%)
No concomitant diabetes drug during the study 924 (27.9%)
Concomitant treatment with diabetes drug during the
study
2392
(72.1%)
Single treatment with:
Sulfonylurea 732 (22.1%)
Glinide 188 (5.7%)
Alpha-glucosidase inhibitor 169 (5.1%)
Biguanide 93 (2.8%)
Thiazolidine 49 (1.5%)
Insulin 156 (4.7%)
Combination therapies:
Sulfonylurea + alpha-glucosidase
inhibitor
229 (6.9%)
Sulfonylurea + biguanide 212 (6.4%)
Sulfonylurea + thiazolidine 91 (2.7%)
Other 473 (14.3%)
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at least 12 weeks and 17 (0.5%) for at least six weeks.
The dose of bezafibrate was 400 mg/day in 2,728
(82.3%) patients and 200 mg/day in 472 (14.2%).
Effect of bezafibrate on blood lipid and glucose levels
Table 3 presents the changes in lipid and glucose para-
meters at baseline and after bezafibrate administration.
All lipid values except LDL-C improved significantly
compared with baseline values. Significant decreases
from baseline were observed for TC, TG, non-HDL-C,
and TG/HDL-C ratio; in contrast, a significant increase
was observed in HDL-C. Although LDL-C levels
decreased significantly in patients with LDL-C ≥ 3.6
mmol/l at baseline (n = 737), they increased significantly
in those with LDL-C < 3.6 mmol/l at baseline (n =
1,489). Thus, LDL-C levels increased significantly over-
a l l .M o r e o v e r ,H b A 1 c ,F B G ,a n dH O M A - Rl e v e l s
decreased significantly.
Effect of bezafibrate on blood glucose levels - subgroup
analysis
Table 4 summarizes the changes in HbA1c concentra-
tions after treatment, classified according to use of dia-
betes drug and baseline HbA1c levels. We analyzed
2,086 patients whose baseline HbA1c values were ≥7.0%.
HbA1c levels decreased significantly by -0.76% from
baseline in all patients. This change was greater in
patients whose baseline HbA1c levels were higher. The
trend analysis showed significant differences between
the HbA1c-subgroups. Similar results were observed in
all medication subgroups classified by diabetes drug
administration before and during the study.
There were 1,464 patients for which we could deter-
mine the change in HbA1c levels as a function of dura-
tion of diabetes (Table 5). HbA1c levels significantly
decreased in all diabetes-duration subgroups, most
strongly in the subgroup with diabetes for < 1 year.
Trend analysis showed significant differences between
the diabetes-duration subgroups. Similar results were
also observed in the medication subgroup of patients
who were not administrated diabetes drug before or
during the study.
We also analyzed HbA1c levels according to concomi-
tant use of a single diabetes drug during the study.
Changes in HbA1c levels for each drug were as follows:
sulfonylureas, n = 536, -0.84%, p < 0.001; glinides, n =
125, -0.82%, p < 0.001; alpha glucosidase inhibitor, n =
70, -0.66%, p < 0.001; biguanide, n = 239, -0.73%, p <
0.001; thiazolidine, n = 28, -0.64%, p = 0.004; insulin: n
= 130, -0.59%, p < 0.001. Each regimen showed a signifi-
cant decrease in HbA1c. There were no significant dif-
ferences between any of the regimens (p = 0.363) (data
not shown).
Factors influencing HbA1c levels
We conducted univariate and multivariate regression
analyses to evaluate the influence of bezafibrate on
HbA1c levels. For initial univariate analysis of 1,854
patients, the difference in HbA1c levels was as an objec-
tive variable. Explanatory variables were patient age, sex,
baseline BMI, baseline HbA1c level, diabetes-drug
administration during the study, duration of diabetes,
and rate of change in levels of each lipid (TC, LDL-C,
TG, and HDL-C). Based on these results, baseline BMI,
baseline HbA1c, diabetes-drug administration, rate of
change in TG, HDL-C, and TC were found to be signifi-
cant variables.
We next performed multivariate regression analysis
using these variables and found that the estimated influ-
ence rate per unit change in each variable on HbA1c
was as follows: baseline HbA1c, -0.489; baseline BMI,
0.016; diabetes-drug administration, 0.176; rate of
change in TG, 0.004; and rate of change in TC, 0.005.
The rate of change in HDL-C was not a significant vari-
able (Table 6). Further, the average rates of change in
TG and TC for all subjects at 24 weeks were -45.4% and
-5.4%, respectively (Table 3). When the rate of change in
Table 3 Analysis of lipid and glycemic parameters
n Baseline mean ± SD After administration mean ± SD Difference Percentage
TC (mmol/L) 3316 5.76 ± 1,03 5.45 ± 0.94 -0.31 ± 1.00 § -5.4%
LDL-C (mmol/L) 2226 3.19 ± 0.95 3.25 ± 0.81 0.05 ± 0.90 ‡ 1.6%
TG (mmol/L) 3316 3.72 ± 2.45 2.03 ± 1.50 -1.69 ± 2.08 § -45.4%
HDL-C (mmol/L) 2818 1.18 ± 0.32 1.34 ± 0.35 0.17 ± 0.25 § 14.0%
non-HDL-C (mmol/L) 2818 4.57 ± 0.99 4.11 ± 0.96 -0.46 ± 0.09 § -10.1%
TG/HDL 1818 3.49 ± 2.75 1.70 ± 1.59 -1.79 ± 2.31 § -51.3%
HbA1c (%) 3316 7.69 ± 1.52 7.22 ± 1.28 -0.47 ± 1.21 § -6.2%
FBG (mmol/L) 2387 9.00 ± 3.46 7.81 ± 2.89 -1.19 ± 3.33 § -13.2%
HOMA-R 102 4.46 ± 4.91 3.38 ± 3.83 -1.08 ± 4.78 † -24.3%
“Difference” indicates the value for the change from baseline. “Percentage” indicates rate of change from baseline. A paired t-test was used to assess statistically
significant differences from baseline for each group. Symbols for p values in this and the tables that follow: †: p < 0.05, ‡: p < 0.01, §: p < 0.001
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altering HbA1c levels were -0.182% and -0.027%, respec-
tively. Next, we analyzed the relationship between rate
of change in TG and amount of change in HbA1c in
3,316 patients (Figure 1). Irrespective of diabetes drug
administration during the study, a strong positive rela-
tionship was observed between the rates of change in
TG and amount of change in HbA1c levels.
Safety
Drug safety was assessed for 5,978 patients. ADRs were
experienced by 306 patients (5.1%) (Table 7). The most
common ADRs were increased blood creatine phospho-
kinase (0.8%), blood creatinine (0.8%), blood urea (0.5%),
renal impairment (0.3%), and aspartate aminotransferase
(0.3%). Severe ADRs were experienced by 17 patients
(0.28%) and mainly included stroke (n = 2, 0.03%), renal
Table 4 HbA1c levels as a function of concomitant diabetes drug use and baseline HbA1c levels
Medication classification HbA1c classification n Baseline mean ± SD After administration mean ± SD Difference
All patients Total 2086 8.46 ± 1.40 7.71 ± 1.31 -0.76 ± 1.38 §
7-8% 1010 7.46 ± 0.29 7.20 ± 0.77 -0.25 ± 0.74 § p < 0.001
8-9% 555 8.44 ± 0.28 7.75 ± 1.02 -0.69 ± 1.01 §
≥9% 521 10.45 ± 1.29 8.64 ± 1.79 -1.81 ± 1.97 §
Diabetes drug use Subtotal 254 7.84 ± 1.04 7.28 ± 1.00 -0.56 ± 1.06 §
Before study: not taken
&
7-8% 186 7.38 ± 0.26 7.06 ± 0.67 -0.32 ± 0.66 p < 0.001
During study: not taken 8-9% 46 8.38 ± 0.26 7.64 ± 1.08 -0.74 ± 1,03 §
≥9% 22 10.64 ± 1.24 8.48 ± 1.85 -2.16 ± 2.03 §
Subtotal 397 8.89 ± 1.66 7.42 ± 1.36 -1.47 ± 1.88 §
Before study: not taken
&
7-8% 147 7.46 ± 0.29 7.06 ± 0.85 -0.39 ± 0.86 § p < 0.001
During study: taken 8-9% 109 8.45 ± 0.29 7.31 ± 0.96 -1.15 ± 0.97 §
≥9% 141 10.73 ± 1.40 7.89 ± 1.84 -2.84 ± 2.30 §
Subtotal 59 8.26 ± 1.33 7.79 ± 1.23 -0.47 ± 1.10 ‡
Before study: taken
&
7-8% 34 7.48 ± 0.28 7.26 ± 0.83 -0.22 ± 0.85 p = 0.003
During study: not taken 8-9% 14 8.50 ± 0.28 8.09 ± 1.03 -0.41 ± 0.93
≥9% 11 10.38 ± 1.67 9.05 ± 1.51 -1.32 ± 1.59 †
Subtotal 1376 8.46 ± 1.33 7.86 ± 1.31 -0.60 ± 1.20 §
Before study: taken
&
7-8% 643 7.48 ± 0.29 7.28 ± 0.76 -0.20 ± 0.73 § p < 0.001
During study: taken 8-9% 386 8.44 ± 0.27 7.88 ± 1.00 -0.56 ± 0.98 §
≥9% 347 10.32 ± 1.22 8.94 ± 1.69 -1.38 ± 1.66 §
Baseline HbA1c levels for 2086 patients were ≥ 7.0%. A paired t-test was used to assess statistically significant differences from baseline for each group. P values
were determined by ANOVA to assess statistically differences from baseline among baseline HbA1c-subgroup
Table 5 HbA1c-levels as a function of the duration of diabetes
Medication
classification
Duration of diabetes
classification
n Baseline maen ±
SD
After administration mean ±
SD
Difference mean ± SD
All cases Total 1464 8.44 ± 1.34 7.76 ± 1.29 -0.68 ± 1.34 §
< 1 year 70 8.65 ± 1.63 7.04 ± 1.08 -1.60 ± 1.82 § p =
0.002
1-5 years 503 8.38 ± 1.35 7.69 ± 1.38 -0.69 ± 1.50 §
5-10 years 432 8.37 ± 1.25 7.81 ± 1.22 -0.56 ± 1.02 §
≥ 10 years 459 8.56 ± 1.36 7.90 ± 1.25 -0.66 ± 1.27 §
Diabetes drug use Subtotal 147 7.81 ± 0.95 7.33 ± 1.05 -0.47 ± 1.00 §
Before study: not taken
&
< 1 year 14 7.72 ± 0.89 6.52 ± 0.75 -1.20 ± 1.31 ‡ p=
0.012
During study: not taken 1-5 years 75 7.73 ± 0.78 7.45 ± 1.08 -0.28 ± 0.88 ‡
5-10 years 38 7.85 ± 1.15 7.38 ± 1.13 -0.47 ± 0.97 ‡
≥ 10 years 20 8.06 ± 1.16 7.36 ± 0.76 -0.70 ± 1,04 ‡
Baseline HBA1c levels for 1464 patients were ≥ 7.0%. P values were determined by ANOVA to assess statistically difference among duration of diabetes-subgroup
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Page 5 of 10impairment (n = 2, 0.03%), elevated blood urea nitrogen
(n = 2, 0.03%), abnormal hepatic function (n = 1,
0.02%), pneumonia (n = 1, 0.02%), rhabdomyolysis (n =
1, 0.02%), hypoglycemia (n = 1, 0.02%), and others. ADR
rate increased slightly in patients concurrently taking
diabetes drugs (4.3% not taking vs. 5.6% taking), but no
apparent clinical differences were observed. One hypo-
glycemia case occurred in a patient concurrently taking
a diabetes drug. Rhabdomyolysis was observed in five
patients, four of whom were treated with a diabetes
drug. No ADRs were observed that could be unequivo-
cally ascribed to concurrent diabetes drug use.
Discussion
In this study, we showed that treatment with bezafibrate
significantly reduced HbA1c levels in patients with dia-
betes complicated by dyslipidemia. This effect was
observed in a baseline HbA1c-dependent manner,
regardless of concurrent use of diabetes drugs. Patients
with a shorter duration of diabetes showed greater
decreases in HbA1c levels. Further, the rate of change in
triglyceride levels was related to changes in HbA1c
levels. Adverse drug reactions occurred in 306 patients
(5.1%), but these were not severe in 289 (94.4%). Taken
together, these results suggest that bezafibrate, which
improves both lipid and blood glucose metabolism,
should be considered suitable for the treatment of dysli-
pidemia in patients with diabetes.
The importance of the rigorous control of glycemia in
diabetes is confirmed by the striking findings that a 1%
reduction in HbA1c level is associated with a 21%
decrease in risk of death related to diabetes [3], and that
a 1-mmol/l increase in TG level is associated with a
32% increased risk of a cardiovascular event [20].
HbA1c correlates significantly with both TG and HDL-
C in patients with type 2 diabetes [21,22]. Further,
patients with type 2 diabetes tend to have higher TG
and lower HDL-C values than dyslipidemic patients
without type 2 diabetes [4]. TG levels are significantly
higher and HDL-C levels significantly lower in patients
with relatively poor glycemic control than in those with
adequate control [21]. These findings confirm the
importance of controlling both TG and HDL-C, in
Table 6 Stepwise multiple regression analysis of the
change in HbA1c levels in relation to explanatory
variables
Explanatory variable Regression
coefficient
SE t-
value
p-
value
Baseline HbA1c (%) -0.489 0.015 -31.79 <
0.001
Baseline BMI (kg/m
2) 0.016 0.006 2.70 0.007
Diabetes drug
administration
0.176 0.049 3.59 <
0.001
Change rate in TG (%) 0.004 0.001 6.34 <
0.001
Change rate in TC (%) 0.005 0.001 4.13 <
0.001
Change rate in HDL-C
(%)
-0.002 0.001 -1.72 0.085
R
2 = 0.3884. Each estimated value indicates the influence in HbA1c per 1 unit
change in each variable. The estimated values of diabetes-drug administration
indicate the rates of influence in patients with and without drug
Figure 1 TG and HbA1c levels in patients depending on use of a diabetes drug. The graphs show the changes in HbA1c levels
determined for all patients (￿), patients taking a diabetes drug (Δ), and patients not taking a diabetes drug (☐).
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diabetes.
Statins have been widely used to treat dyslipidemia,
and evidence supports their role in preventing cardio-
vascular events [23-26]. However, fibrates, including
bezafibrate, generally haveas t r o n g e re f f e c to nT Ga n d
HDL-C than statins. Atorvastatin 20 mg/day and rosu-
vastatin 10 mg/day reduced TG levels by 4.6% and
36.4%, and increased or decreased HDL-C levels by 4.5%
and 2.0%, respectively [27]. Although rosuvastatin (5-20
mg/day) decreased TG levels by 29%-31% and increased
HDL-C levels by 12.4%-16.7%, bezafibrate (400 mg/day)
decreased TG levels by 45% and increased HDL-C levels
by 43% [28]. The present study also revealed that bezafi-
brate decreased the rate of change in TG level by 45.4%
and the rate of increase in HDL-C level by 14.0% (Table
3). These results suggest that the effect of fibrates on
TG and HDL-C levels is stronger than that of statins.
Although controversial, evidence suggests that fibrates
have a lower association with cardiovascular events than
statins. Indeed, a recent meta-analysis of 18 fibrate trials
[29] revealed that fibrates significantly reduce the risk of
cardiovascular events, but not uniformly [30-34]. In the
ACCORD study, cardiovascular disease risk in 5,581
patients [30] receiving combination therapy with a statin
plus a fenofibrate was no different than that in patients
with statin monotherapy. Further, in the BIP study of
3,090 patients [32], bezafibrate did not significantly
reduce the primary endpoint (fatal or nonfatal myocar-
dial infarction or sudden death).
Common findings between these studies [30-33] are as
follows: first, baseline TG values were not high, aver-
aging 1.8 mmol/l in ACCORD and 1.6 mmol/l in BIP.
Second, subgroup analysis of patients with baseline TG
values ≥ 2.2 mmol/l exhibited potent (31%) risk reduc-
tion in ACCORD and 39.5% (P = 0.02) in BIP. Results
of the FIELD study were similar [34]. We therefore con-
clude that fibrates can play a prominent role in reducing
the risk of cardiovascular events in patients with high
TG levels. Further, recent reports indicate that statin
therapy is associated with a slightly higher risk of devel-
oping diabetes [35,36]. These findings suggest that if a
patient is at low risk for cardiovascular disease, the
potential for statins to increase diabetes risk should be
taken into account.
Bezafibrate reduces blood glucose levels in patients
with type 2 diabetes [14,15]. Elkeles et al. reported that
bezafibrate significantly decreased the combined inci-
d e n c eo fi s c h e m i cc h a n g ei nE C Ga n dd o c u m e n t e d
myocardial infarction in patients with type 2 diabetes
[37]. Further, Tenenbaum et al. reported that bezafibrate
decreased the development and delayed the onset of
type 2 diabetes in patients with impaired fasting glucose
[38]. Therefore, bezafibrate may be more suitable than
statins for treating dyslipidemic patients with type 2 dia-
betes if their cardiovascular risk is low. To our knowl-
edge, our present study is the first to demonstrate the
beneficial effects of bezafibrate on lipid and glucose
metabolism in a large number of patients with diabetes.
Consistent with studies cited above, we showed here
that bezafibrate improved blood glucose and lipid levels.
All lipid values except LDL-C improved significantly
from baseline, with TG, HDL-C levels and the TG/HDL
ratio in particular showing significant changes. Further,
HbA1c, FBG, and HOMA-R improved significantly from
baseline. HbA1c levels decreased by -0.47% in all
patients and by -0.76% in patients with baseline HbA1c
levels ≥7.0%. Notably, bezafibrate showed a potent hypo-
glycemic effect regardless of concurrent diabetes drug
use. On analysis stratified by diabetes duration, bezafi-
brate alone reduced HbA1c in all subgroups, most nota-
bly in those with diabetes for < 1 year. Therefore,
Table 7 Adverse drug reactions in the safety analysis set
Adverse drug reactions Cases Cases without diabetes drug Cases with diabetes drug
Number 5978 2382 3596
ADRs 306 (5.1%) 103 (4.3%) 203 (5.6%)
Blood creatine phosphokinase increased 48 (0.8%) 17 (0.7%) 31 (0.9%)
Blood creatinine increased 46 (0.8%) 18 (0.8%) 28 (0.8%)
Blood urea increased 29 (0.5%) 10 (0.4%) 19 (0.5%)
Renal impairment 19 (0.3%) 8 (0.3%) 11 (0.3%)
Aspartate aminotransferase increased 18 (0.3%) 7 (0.3%) 11 (0.3%)
Myalgia 17 (0.3%) 6 (0.3%) 11 (0.3%)
Hepatic function abnormal 15 (0.3%) 2 (0.1%) 13 (0.4%)
Pruritus 13 (0.2%) 6 (0.3%) 7 (0.2%)
Alanine aminotransferase increased 13 (0.2%) 5 (0.2%) 8 (0.2%)
Rash 12 (0.2%) 6 (0.3%) 6 (0.2%)
Dyspepsia 7 (0.1%) 1 (0.0%) 6 (0.2%)
Others 72 (1.2%) 19 (0.8%) 53 (1.5%)
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early-onset type 2 diabetes coexisting with hypertrigly-
ceridemia. Alternatively, hyperglycemic patients with
inadequate blood glucose control might benefit from
concomitant administration of bezafibrate and a diabetes
drug.
We also demonstrated here that as TG levels
decreased, those of HbA1c decreased by 0.47% in all
patients (Figure 1 and Table 3). Ogawa reported that
bezafibrate decreased TG levels by 50% and decreased
HbA1c levels from 7.2% to 6.9% in patients with type 2
diabetes [16]. Taniguchi reported similar results [15]. In
contrast, the three-year SENDCAP study of 164 patients
with type 2 diabetes reported that while bezafibrate
decreased TG significantly, the change in HbA1c levels
over the course of the study was not significant between
bezafibrate and the control groups [37]. Although long-
term studies will be required to confirm this observa-
tion, average baseline TG levels were lower than those
cited above, leading us to conclude that this may have
caused the change in HbA1c levels.
Bays et al. reported the following two relationships
between fatty acid levels and type 2 diabetes [39]: (1)
chronically increased plasma free-fatty acid induces
hepatic and muscle insulin resistance and impairs insu-
lin secretion; and (2) enlarged fat cells become insulin-
resistant, with diminished capacity to store fat. When
the storage capacity in adipocyte tissue is exceeded,
lipids flow over into muscle and liver, causing muscle
and hepatic insulin resistance. Bezafibrate has been
reported to increase fatty acid degradation via beta-oxi-
dation in the peroxisomes and mitochondria [40-42].
Further, Van der Ziji et al. reported that pancreatic fatty
acid accumulation is related to b cell dysfunction [43],
and Fernandes-Santos et al. reported that bezafibrate
prevented pancreatic fat accumulation and hypertrophy
in mice while attenuating glucose intolerance and insu-
lin resistance [44]. These studies suggest that plasma
free fatty acid and ectopic fat accumulation involve glu-
cose tolerance, and that bezafibrate improves glucose
tolerance through fatty acid degradation via activating
beta-oxidation.
ADRs were observed in 306 (5.1%) of 5,978 patients in
the safety analysis group. The most frequent were
increases in blood levels of creatine phosphokinase
( 0 . 8 % ) ,c r e a t i n i n e( 0 . 8 % )a n du r e a( 0 . 5 % ) .N os p e c i f i c
differences were observed related to the use or non-use
of diabetes drugs. Betteridge and O’ Bryan-Tear [45]
and Beggs et al. [46] reported, respectively, that 7.7% (7/
91) and 5.4% (7/130) of ADRs were caused by bezafi-
brate administration. The rate of ADRs in the present
study is comparable to their result.
In the present study, concurrent use of the biguanide
drug metformin was 16.6%. The guidelines of the
American Diabetes Association and the European Asso-
ciation for the Study of Diabetes recommend initial
treatment of type 2 diabetes mellitus with metformin
[47]. Since 2009, metformin treatment has been
restricted to cases that do not respond to sulfonylureas.
The maximum dose was 750 mg/day, which, until 2010
in Japan at least, is much less than the dose adminis-
tered in Western countries. Therefore, the results of
clinical trials in Western countries cannot be directly
applied to Japanese patients. Further, the majority of
Japanese patients with type 2 diabetes mellitus are less
obese and less insulin-resistant than European and
American patients [48]. Currently in Japan, the maxi-
mum dose of metformin is 2,250 mg/day.
Our study has several important limitations. First, it
was conducted under a prospective observational cohort
design with no control arm, and it was not possible to
eliminate all confounding factors. Interpretation of our
findings, therefore, requires caution until further studies
with controls can be conducted. Second, changes in
body weight, modification of lifestyle, and use of dia-
betes drugs were not recorded, and the effects of these
variables on glucose metabolism cannot be ruled out. It
is, however, important to note that other studies [15,16]
reported result similar to ours presented here. More-
over, of the 254 patients not treated with diabetes drugs
in the present study, average HbA1c levels decreased by
0.56% after administration of bezafibrate (Table 4),
strongly suggesting that bezafibrate alone lowers blood
glucose levels. Third, for logistic, economic and other
reasons, laboratory measurements could only be per-
formed at each of the 1,066 institutions and not in a
central laboratory. Although the JDS, in collaboration
with the Japan Society of Clinical Chemistry, developed
a national standardization scheme for determining
HbA1c levels in 1995 in Japan [49], and Nihei et al.
reported that commutability among the most frequently
used analytical techniques in Japan was secured at a spe-
cific level [50], differences in HbA1c levels determined
by different methods and laboratories cannot be ruled
out. Nevertheless, we believe that the present results
demonstrate convincingly the beneficial effects of bezafi-
brate in patients with type 2 diabetes in clinical settings.
Conclusions
This 24-week prospective observational study of dyslipi-
demic patients with diabetes or hyperglycemia showed
that bezafibrate significantly reduced HbA1c levels as a
function of baseline HbA1c level regardless of concur-
rent use of diabetes drugs. Further, a correlation was
apparent between the rates of change of triglyceride and
HbA1c levels. Patients with type 2 diabetes tended to
have higher TG and lower HDL-C values [4]. We there-
fore conclude that the control of both TG and blood
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Page 8 of 10glucose levels is an important consideration in the treat-
ment of dyslipidemia complicated by diabetes and that
physicians should consider that bezafibrate is an effec-
tive therapy in these patients.
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